Lattice Advances Low Power FPGA Leadership with New Small and Mid-range FPGA Offerings
10.12.2024 19:00:00 CET | Business Wire | Press release
‒ Introduces Lattice Nexus 2 next-gen small FPGA platform, extends mid-range portfolio with Lattice Avant 30 and Avant 50 devices, and enhances capabilities of application-specific solution stacks and design software tools ‒
Today, at Lattice Developers Conference 2024, Lattice Semiconductor (NASDAQ: LSCC) expanded its edge to cloud FPGA innovation leadership with the launch of exciting new hardware and software solutions. The new Lattice Nexus™ 2 next-gen small FPGA platform and the first device family based on the platform, Lattice Certus™-N2 general purpose FPGAs, offer advanced connectivity, optimized power and performance, and class-leading security. Lattice also announced new mid-range FPGA device capacity options – Lattice Avant™ 30 and Avant™ 50 – and new versions of Lattice design software tools and application-specific solution stacks to help accelerate customer time-to-market.
“At Lattice, we are proud to lead technological advancements in low power, small form factor FPGAs, ensuring our customers have the optimal devices, tools, and solutions to design groundbreaking applications that are power efficient, fast, and secure,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “From the edge to the cloud across a variety of industries, FPGAs stand at the forefront of innovation, and we’re committed to delivering versatile and robust small and mid-range FPGA solutions that enable our customers and partners to unlock their full potential.”
Advancing Small FPGA Innovation
The new Lattice Nexus 2 small FPGA platform combines connectivity advancements, power and performance optimizations, and leading security and reliability capabilities to meet the growing demand for edge applications requiring efficient processing, bridging, and control capabilities.
Built on the proven 16 nm FinFET TSMC process technology, Lattice Nexus 2 continues company’s low power, small FPGA leadership equipping customers with
-
Power Efficiency
- Up to 3X lower power than similar class competitive devices, enabling power and thermal design efficiencies, improved operating costs, and enhanced reliability.
- Up to 10X energy efficient edge sensor monitoring than similar class competitive devices.
-
Performance
- Up to 3.2X faster MIPI speed than similar class competitive devices for faster connectivity and data transfer.
- Up to 10X faster configuration time than similar class competitive devices enhancing overall efficiency, fault tolerance, and security in safety-critical applications.
-
Form Factor
- Up to 5X smaller size than similar class competitive devices, enabling simplified, efficient system designs.
-
Connectivity
- Combines multi-protocol 16G SERDES with PCIe® Gen 4 controller, high performance I/O, high speed LPDDR4 memory interface support, and industry-leading MIPI D & C-PHY up to 7.98 Gbps.
-
Security
- Industry-leading security with 256-bit AES-GCM and SHA3-512; compliant with FIPS 140-3 level 2 standards.
- Crypto agility, post-quantum ready, and anti-temper protection.
- Integrated flash enabling faster and more secure configuration.
- End user options for customers’ data-in-motion security needs.
The Lattice Nexus 2 platform is architected for scalability that will enable the rapid development of multiple new device families, starting today with the launch of the Lattice Certus™-N2 general purpose FPGA family. Lattice Certus-N2 FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.
Extending Mid-Range FPGA Portfolio
Built on the award-winning Lattice Avant platform, the Avant 30 and Avant 50 offers new capacity options for customers to enable edge optimized and advanced connectivity applications development. These devices provide customers more options for connectivity, functional capacity, and features.
Expanded Solution Stacks
Lattice announced new versions of Lattice Radiant™ and Lattice Propel™ software tools that support the new Lattice Nexus 2 FPGA platform, Lattice Certus-N2 FPGA family, and Lattice Avant devices, alongside new features including RISC-V® variants and improved debug, power calculation, and ease-of-use.
Lattice also announced four solution stack updates in edge AI with Lattice sensAI™, embedded vision with Lattice mVision™, factory automation with Lattice Automate™, and automotive designs with Lattice Drive™. These updates include improved performance with enhanced application-specific features and expanded IP, demo, and reference designs.
These announcements were made today during the livecast at Lattice Developers Conference 2024, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 10-11, 2024, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.
For more information on the new products, please read the latest blog and visit:
- Lattice Nexus 2 FPGA platform
- Lattice Certus-N2 FPGA
- Lattice sensAI solution stack
- Lattice mVision solution stack
- Lattice Automate solution stack
- Lattice Drive solution stack
- Lattice Propel
- Lattice Radiant
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210483055/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom